Form 4: Axsome CEO Sells Shares After Exercising Expiring Options

Axsome Therapeutics CEO Herriot Tabuteau executed a series of pre-planned transactions, exercising expiring stock options and subsequently selling the acquired common stock.

Summary

• Herriot Tabuteau, CEO, Director, and 10% Owner of Axsome Therapeutics, Inc. (AXSM), engaged in a series of stock option exercises and subsequent share sales between January 5 and January 7, 2026.
• The transactions were executed pursuant to a pre-approved 10b5-1 plan.
• The stock option exercises were necessary due to the attainment of the 10-year expiration date of the options, which were set to expire on May 27, 2026.
• On January 5, 2026, 78,703 shares were acquired at an exercise price of $8.02 per share and immediately sold at a weighted average price of $171.28 per share.
• On January 6, 2026, 29,450 shares were acquired at an exercise price of $8.02 per share and immediately sold at a weighted average price of $172.33 per share.
• On January 7, 2026, 31,261 shares were acquired at an exercise price of $8.02 per share and immediately sold at a weighted average price of $170.38 per share.
• Following these transactions, Herriot Tabuteau directly beneficially owns 7,229 shares of common stock and indirectly beneficially owns 7,344,500 shares through an entity where voting and dispositive power resides.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, the transactions are routine, pre-planned under a 10b5-1 plan, and driven by the expiration of stock options, rather than a discretionary decision to sell based on new negative information. The significant profit from the option exercise is a positive for the insider.

Positives

• The transactions were conducted under a pre-approved 10b5-1 plan, indicating a pre-scheduled event rather than a new discretionary selling decision.
• The sale prices significantly exceed the exercise prices, demonstrating a substantial gain for the reporting person on these specific option exercises.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, although the context of expiring options mitigates this concern.

Risks

• No new specific risks are identified in this Form 4 filing beyond the general market perception of insider selling, which is mitigated by the pre-planned nature and reason for the transactions.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports insider trading activity.

Management Comments

• The exercise of stock options was necessary due to the attainment of the 10-year expiration date of such options.
• All reported transactions were pursuant to a pre-approved 10b5-1 plan.
• The sales represent the subsequent disposition of the underlying shares acquired from the aforementioned exercise of stock options.

Industry Context

Insider transactions, particularly those involving the exercise of expiring stock options and subsequent sales under a 10b5-1 plan, are a common occurrence across all industries for executives managing their equity compensation and diversifying personal holdings. This activity is generally considered routine.

Comparison to Industry Standards

• The practice of executives exercising expiring stock options and selling the underlying shares is a standard component of equity compensation management across publicly traded companies.
• The use of a Rule 10b5-1 plan for such transactions is also a widely adopted best practice, providing an affirmative defense against insider trading allegations by pre-scheduling trades.

Related Party Transactions

• 7,344,500 shares are held by an entity of which the reporting person has voting and dispositive power, making the reporting person the indirect beneficial owner of these shares.

Stakeholder Impact

• Shareholders may observe the insider selling, but the context of expiring options and a 10b5-1 plan typically mitigates concerns about management's confidence in the company's future.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The reported transactions are routine insider activity, involving the exercise of expiring stock options and subsequent sale of shares under a pre-approved 10b5-1 plan. This type of transaction is common for executives managing their equity compensation and does not typically signal a change in the company's fundamental outlook or warrant a shift in investment recommendation based solely on this filing.

Keywords

Axsome Therapeutics, AXSM, Insider Trading, Form 4, Stock Options, CEO, Share Sale, 10b5-1 Plan, Equity Compensation